Diabetes CV Endpoints Suffer Renewed Criticism At Empagliflozin Meeting
Executive Summary
EMPA-REG data for Boehringer/Lilly's Jardiance highlight need to rethink diabetes trials' current three-point MACE endpoint that is heavily focused on atherosclerosis, FDA advisors say.